Two key senators are working to build support for a bill aimed at lowering insulin prices and capping monthly copays under commercial and Medicare insurance plans.
The move is the next step in advancing one of Democrats’ most popular provisions from a stalled reconciliation bill ahead of a tough midterm election, although it’s not clear whether it has the votes to pass. In March, the House passed its own standalone version, sponsored by frontline Democrats, to cap insulin copays.
The Senate bill, released Wednesday by Senate Diabetes Caucus Co-Chairs Jeanne Shaheen, D-N.H., and Susan Collins, R-Maine, aims to entice drugmakers to lower their list prices to 2021 net Medicare rates by blocking pharmacy benefit managers from negotiating drug rebates or other discounts.
